Medidata Scales AI Across 500+ Clinical Trials, Accelerates Study Builds
Event summary
- Medidata's AI technology has been deployed across over 500 clinical studies in the last decade, with 120 AI-supported studies starting in 2025.
- New AI Study Build capability reduces study build times by leveraging generative AI and study protocols.
- Dot, Medidata's AI orchestrator, expands to coordinate domain-specific AI Companions across the platform.
- Medidata's AI engine is built on data from over 38,000 trials, aiming to accelerate time-to-market for sponsors and CROs.
The big picture
Medidata's expansion of AI capabilities aligns with the life sciences industry's shift toward embedded, enterprise AI solutions. The company's focus on clinically-fluent, regulatory-grade AI positions it to drive efficiency in clinical trials, addressing the growing demand for faster and more transparent trial processes. With over 38,000 trials in its dataset, Medidata is leveraging its extensive experience to redefine clinical trial success through intelligent automation.
What we're watching
- AI Adoption Pace
- The pace at which Medidata can scale AI across additional clinical studies and maintain regulatory compliance.
- Competitive Differentiation
- Whether Medidata's AI capabilities will sustain a competitive edge in the clinical trial solutions market.
- Market Impact
- How the acceleration of study builds will affect the speed of bringing therapies to market and its impact on the biopharmaceutical industry.
Related topics